Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Susan Bellaire"'
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 3, Pp 291-301 (2019)
Inhibition of the enzyme 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) represents a potential mechanism for improving pain conditions. ASP3662 is a potent and selective inhibitor of 11β‐HSD1. Two phase I clinical studies were conducted
Externí odkaz:
https://doaj.org/article/4136bf49b098469fa7b9596299aa65f8
Autor:
Sivagurunathan Sutharsan, Arian Pano, Eva Santermans, Olivier Van de Steen, Katja Conrath, Wolfgang Gleiber, Sam Corveleyn, Nancy Van Osselaer, Susan Bellaire, Axel Kempa, Carsten Schwarz, Silke van Koningsbruggen-Rietschel, K. Muller, Rainald Fischer, Dieudonné Bwirire, Andreas Hector
Publikováno v:
Journal of Cystic Fibrosis. 19:292-298
Background Triple combinations of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators demonstrate enhanced clinical efficacy in CF patients with F508del mutation, compared with modest effects of dual combinations. GLPG2737 was
Autor:
Teresa Lara-Jaime, Beata Planeta, David Matuskey, Richard E. Carson, Jim Ropchan, Anupama Shirali, Shannan Henry, Yiyun Huang, Susan Bellaire, Michael Kapinos, David Labaree, Jean-Dominique Gallezot, Mark Walzer, Richard Pracitto, Nabeel Nabulsi, Gerard J. Marek, Hong Gao, Shu-fei Lin, Nancy Yuan
Publikováno v:
Journal of Nuclear Medicine. 60:1140-1146
The 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme converts cortisone to cortisol and participates in the regulation of glucocorticoid levels in tissues. 11β-HSD1 is expressed in the liver, kidney, adipose tissue, placenta, and brain. 1
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 12, Iss 3, Pp 291-301 (2019)
Clinical and Translational Science, Vol 12, Iss 3, Pp 291-301 (2019)
Inhibition of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) represents a potential mechanism for improving pain conditions. ASP3662 is a potent and selective inhibitor of 11β-HSD1. Two phase I clinical studies were conducted to ass
Autor:
Kors van der Ent, Katja Conrath, Predag Minić, J. Stuart Elborn, Herman de Kock, Eva Van Braeckel, Pavel Drevinek, David E. Geller, Scott C. Bell, Stijn Verhulst, K. Muller, Peter J. Barry, Susan Bellaire, Barry J. Plant, D. Kanters, Olivier Van de Steen, Kris De Boeck
Publikováno v:
Journal of cystic fibrosis
JOURNAL OF CYSTIC FIBROSIS
JOURNAL OF CYSTIC FIBROSIS
BACKGROUND: Several treatment approaches in cystic fibrosis (CF) aim to correct CF transmembrane conductance regulator (CFTR) function; the efficacy of each approach is dependent on the mutation(s) present. A need remains for more effective treatment
Autor:
Jean-Dominique, Gallezot, Nabeel, Nabulsi, Shannan, Henry, Richard, Pracitto, Beata, Planeta, Jim, Ropchan, Shu-Fei, Lin, David, Labaree, Michael, Kapinos, Anupama, Shirali, Teresa, Lara-Jaime, Hong, Gao, David, Matuskey, Mark, Walzer, Gerard J, Marek, Susan, Bellaire, Nancy, Yuan, Richard E, Carson, Yiyun, Huang
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 60(8)
The 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme converts cortisone to cortisol and participates in the regulation of glucocorticoid levels in tissues. 11β-HSD1 is expressed in the liver, kidney, adipose tissue, placenta, and brain. 1